A desirable approach to control AIDS would be to develop a vaccine that could confer long-term immunity against the human immunodeficiency virus (HIV) and at the same time be easily administered worldwide. We have identified two highly antigenic vaccinia virus proteins of 14K and 39K and shown that, when we covalently link 14K to HIV-1 env or gag and expressed the fusion proteins in cells infected with HIV-vaccinia virus recombinants we observe the following: 1) the fusion proteins are localized on the cell surface in the form of oligomers, 2) are not cleaved or released from the cells, 3) env is poorly glycosylated and 4) when the recombinant viruses are inoculated in mice there is induction of specific antibodies against HIV env and gag. The safety of these HIVvaccinia virus recombinants was further assesed in immunosuppressed mice. In light of the uniqueness of the 14K-fusion protein, we suggest that HIV-vaccinia fusion proteins may provide an effective means of enhancing and modifying B and T-cell responses against HIV infection. The goal of this proposal is to determine whether the immune response elicited by HIV-vaccinia fusion proteins is more effective against HIV than the immune response elicited by the native proteins. We will use the mouse model because it will provide a wider range of data that otherwise we could not practically obtain from a primate model. The long-term objective of this study is to develop a safe vaccine that can be tested in primates and eventually in humans. The proposed project will consist of the following main objectives: 1. To construct HIV-vaccinia recombinant viruses (wild type and attenuated) expressing fusion proteins containing the full-length sequence of vaccinia 14K or 39K proteins fused to complete or partial sequence of HIV-1 env and gag and study their mode of expression in cultured cells. 2. To characterize the extent of the humoral immune response elicited in mice primed with HIV-vaccinia recombinant viruses and boosted with either the live recombinant virus, purified non-fused or purified fused proteins and to define the mode of inhibition of HIV cytopathogenicity by the specific antisera. 3. To characterize the extent of the cellular immune response in mice of different haplotype immunized as described in objective 2. If the fusion proteins elicit a more effective and sustained humoral and cellular immune response to HIV antigens than the non-fused proteins, then this novel approach may produce a useful vaccine against HIV to be used in either seronegative (as a preventive measure) or seropositive human subjects (as therapeutic agent).

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI032361-02
Application #
3147383
Study Section
AIDS and Related Research Study Section 1 (ARRA)
Project Start
1992-07-01
Project End
1995-06-30
Budget Start
1993-07-01
Budget End
1994-06-30
Support Year
2
Fiscal Year
1993
Total Cost
Indirect Cost
Name
Suny Downstate Medical Center
Department
Type
Schools of Medicine
DUNS #
068552207
City
Brooklyn
State
NY
Country
United States
Zip Code
11203
Myylkova, Z; Lee, S B; Rodriguez, D et al. (1997) Bcl-2 prevents nitric oxide-mediated apoptosis and poly(ADP-ribose) polymerase cleavage. FEBS Lett 403:273-8
Lee, S B; Rodriguez, D; Rodriguez, J R et al. (1997) The apoptosis pathway triggered by the interferon-induced protein kinase PKR requires the third basic domain, initiates upstream of Bcl-2, and involves ICE-like proteases. Virology 231:81-8
Taylor, D R; Lee, S B; Romano, P R et al. (1996) Autophosphorylation sites participate in the activation of the double-stranded-RNA-activated protein kinase PKR. Mol Cell Biol 16:6295-302
Lee, S B; Bablanian, R; Esteban, M (1996) Regulated expression of the interferon-induced protein kinase p68 (PKR) by vaccinia virus recombinants inhibits the replication of vesicular stomatitis virus but not that of poliovirus. J Interferon Cytokine Res 16:1073-8
Rodriguez, D; Rodriguez, J R; Esteban, M (1995) Enhanced proteolytic processing of the human immunodeficiency virus type 1 envelope protein in murine Ltk(-) cells. AIDS Res Hum Retroviruses 11:81-5
Myylkova, Z; Esteban, M (1995) Inhibition of vaccinia virus DNA replication by inducible expression of nitric oxide synthase. J Immunol 155:5711-8
Rodriguez, D; Esteban, M; Rodriguez, J R (1995) Vaccinia virus A17L gene product is essential for an early step in virion morphogenesis. J Virol 69:4640-8
Myylkova, Z; Esteban, M (1994) Interferon-gamma severely inhibits DNA synthesis of vaccinia virus in a macrophage cell line. Virology 198:731-5
Rodrigues, M; Li, S; Murata, K et al. (1994) Influenza and vaccinia viruses expressing malaria CD8+ T and B cell epitopes. Comparison of their immunogenicity and capacity to induce protective immunity. J Immunol 153:4636-48
Rodriguez, D; Rodriguez, J R; Esteban, M (1993) The vaccinia virus 14-kilodalton fusion protein forms a stable complex with the processed protein encoded by the vaccinia virus A17L gene. J Virol 67:3435-40

Showing the most recent 10 out of 11 publications